Type II achalasia with focal elevated pressures: A distinct manometric and clinical sub-group.
EUS
achalasia
contraction
esophagus
manometry
Journal
Neurogastroenterology and motility
ISSN: 1365-2982
Titre abrégé: Neurogastroenterol Motil
Pays: England
ID NLM: 9432572
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
15
07
2022
received:
11
05
2022
accepted:
27
07
2022
pubmed:
17
8
2022
medline:
6
12
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Type II achalasia (Ach2) is distinguished from other achalasia sub-types by the presence of panesophageal pressurization (PEP) of ≥30 mmHg in ≥20% swallows on high-resolution manometry (HRM). Variable manometric features in Ach2 have been observed, characterized by focal elevated pressures (FEPs) (focal/segmental pressures ≥70 mmHg within the PEP band) and/or high compression pressures (PEP ≥70 mmHg). This study aimed to examine clinical and physiologic variables among sub-groups of Ach2. This retrospective single center study performed over 3 years (1/2019-1/2022) included adults with Ach2 on HRM who underwent endoscopic ultrasound (EUS), functional lumen imaging probe (FLIP), and/or barium esophagram (BE) prior to therapy. Patients were categorized into two overarching sub-groups: Ach2 without FEPs and Ach2 with FEPs. Demographic, clinical, and physiologic data were compared between these sub-groups utilizing unpaired univariate analyses. Of 53 patients with Ach2, 40 (75%) were without FEPs and 13 (25%) had FEPs. Compared with the Ach2 sub-group without FEPs, the Ach2 sub-group with FEPs demonstrated a significantly thickened distal esophageal circular muscle on EUS (1.4 mm [SD 0.9] vs. 2.1 [0.7]; p = 0.02), higher prevalence of tertiary contractions on BE (46% vs. 100%; p = 0.0006), lower esophagogastric junction distensibility index (2.2mm We identified a distinct sub-group of type II achalasia on HRM, defined as type II achalasia with focal elevated pressures. This sub-group uniquely exhibits spastic features and may benefit from personalized treatment approaches.
Sections du résumé
BACKGROUND
Type II achalasia (Ach2) is distinguished from other achalasia sub-types by the presence of panesophageal pressurization (PEP) of ≥30 mmHg in ≥20% swallows on high-resolution manometry (HRM). Variable manometric features in Ach2 have been observed, characterized by focal elevated pressures (FEPs) (focal/segmental pressures ≥70 mmHg within the PEP band) and/or high compression pressures (PEP ≥70 mmHg). This study aimed to examine clinical and physiologic variables among sub-groups of Ach2.
METHODS
This retrospective single center study performed over 3 years (1/2019-1/2022) included adults with Ach2 on HRM who underwent endoscopic ultrasound (EUS), functional lumen imaging probe (FLIP), and/or barium esophagram (BE) prior to therapy. Patients were categorized into two overarching sub-groups: Ach2 without FEPs and Ach2 with FEPs. Demographic, clinical, and physiologic data were compared between these sub-groups utilizing unpaired univariate analyses.
KEY RESULTS
Of 53 patients with Ach2, 40 (75%) were without FEPs and 13 (25%) had FEPs. Compared with the Ach2 sub-group without FEPs, the Ach2 sub-group with FEPs demonstrated a significantly thickened distal esophageal circular muscle on EUS (1.4 mm [SD 0.9] vs. 2.1 [0.7]; p = 0.02), higher prevalence of tertiary contractions on BE (46% vs. 100%; p = 0.0006), lower esophagogastric junction distensibility index (2.2mm
CONCLUSIONS AND INFERENCES
We identified a distinct sub-group of type II achalasia on HRM, defined as type II achalasia with focal elevated pressures. This sub-group uniquely exhibits spastic features and may benefit from personalized treatment approaches.
Identifiants
pubmed: 35972282
doi: 10.1111/nmo.14449
pmc: PMC9722506
mid: NIHMS1833765
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14449Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK125266
Pays : United States
Organisme : NIDDK NIH HHS
ID : P01 DK117824
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007202
Pays : United States
Informations de copyright
© 2022 John Wiley & Sons Ltd.
Références
Gastroenterology. 2018 Aug;155(2):327-336
pubmed: 29733830
World J Gastroenterol. 2007 Mar 7;13(9):1335-46
pubmed: 17457963
Dig Dis Sci. 1997 Feb;42(2):307-13
pubmed: 9052511
Am J Physiol Gastrointest Liver Physiol. 2002 Jun;282(6):G1016-23
pubmed: 12016127
Gastrointest Endosc Clin N Am. 2001 Apr;11(2):281-92, vi
pubmed: 11319062
Gastroenterology. 2013 Nov;145(5):954-65
pubmed: 23973923
Endosc Int Open. 2015 Jun;3(3):E195-201
pubmed: 26171430
Gastroenterology. 2013 Apr;144(4):718-25; quiz e13-4
pubmed: 23277105
Neurogastroenterol Motil. 2021 Jan;33(1):e14058
pubmed: 33373111
Neurogastroenterol Motil. 2008 Aug;20(8):869-76
pubmed: 18452508
Gastrointest Endosc. 2021 Apr;93(4):861-868.e1
pubmed: 32721488
Neurogastroenterol Motil. 2021 Mar;33(3):e13932
pubmed: 32608147
Radiology. 1989 Nov;173(2):419-22
pubmed: 2798872
Am J Physiol. 1998 Oct;275(4):G805-11
pubmed: 9756512
Gastroenterology. 1999 Jul;117(1):26-31
pubmed: 10381906
Gastroenterol Hepatol (N Y). 2017 Jul;13(7):411-421
pubmed: 28867969
Neurogastroenterol Motil. 2005 Apr;17(2):200-6
pubmed: 15787940
Surg Endosc. 2019 Mar;33(3):886-894
pubmed: 30054739
Dig Dis Sci. 2021 Oct;66(10):3490-3494
pubmed: 33089487
Curr Opin Gastroenterol. 2013 Jul;29(4):421-30
pubmed: 23739655
Ann Transl Med. 2021 May;9(10):906
pubmed: 34164540
J Neurogastroenterol Motil. 2021 Jan 30;27(1):63-70
pubmed: 32675389
Am J Physiol Gastrointest Liver Physiol. 2016 May 1;310(9):G689-95
pubmed: 26950858
Gastrointest Endosc. 2021 Jun;93(6):1304-1312
pubmed: 33058884